23:00 EST Cathie Wood’s ARK Investment buys 120K shares of Crispr Therapeutics (CRSP) today
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $89 from $90 at BofA
- CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies
- Crispr Therapeutics highlights anticipated 2026 milestones
- Crispr Therapeutics says Casgevy exceeded $100M in revenue in 2025
- Crispr Therapeutics price target lowered to $90 from $93 at BofA